GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (STU:DMP) » Definitions » 14-Day RSI

Dermapharm Holding SE (STU:DMP) 14-Day RSI : 47.74 (As of Jun. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-22), Dermapharm Holding SE's 14-Day RSI is 47.74.

The industry rank for Dermapharm Holding SE's 14-Day RSI or its related term are showing as below:

STU:DMP's 14-Day RSI is ranked worse than
50.48% of 1145 companies
in the Drug Manufacturers industry
Industry Median: 45.94 vs STU:DMP: 47.74

Competitive Comparison of Dermapharm Holding SE's 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's 14-Day RSI falls into.



Dermapharm Holding SE  (STU:DMP) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermapharm Holding SE  (STU:DMP) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Dermapharm Holding SE 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE (STU:DMP) Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs and natural remedies. Its portfolio of products includes cosmetics, nutritional supplements and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals and cosmetics products. Parallel import brands business operates under the AxiCorp brand.

Dermapharm Holding SE (STU:DMP) Headlines

No Headlines